文献速递肺外科

机器人肺叶切除治疗非小细胞肺癌的长期生存:多中心研究

The long-term survival of robotic lobectomy for non-small cell lung cancer: A multi-institutional study.
PubMed 文献 · J Thorac Cardiovasc Surg · 2017-09-18

该研究基于4家机构前瞻性机器人数据库,回顾性分析1339例连续接受机器人肺叶切除的非小细胞肺癌(NSCLC)患者。中位随访30个月,5年分期特异性生存从IA期83%到IIIB期31%,局部复发累积发生率仅3%,转移累积发生率15%;作者认为肿瘤学结果令人鼓舞,尤其对病理N2患者,但仍需进一步随访。

要点

  • 机器人肺叶切除治疗NSCLC的5年分期生存IA期83%、IIIA期62%,局部复发累积发生率仅3%。
  • 中转率9%(出血相关2%),主要并发症8%,30天和90天手术死亡率分别为0.2%和0.5%。
  • 病理N2(IIIA期)患者5年生存62%,作者认为结果令人鼓舞但需进一步随访。

核心结论

  • 机器人肺叶切除治疗NSCLC的肿瘤学结果令人鼓舞,尤其对病理N2患者,但仍需进一步随访和研究。

研究设计与样本

  • 多中心回顾性研究,纳入4家机构前瞻性机器人数据库中的1339例连续患者(男性55%,中位年龄68岁)。

主要发现

  • 中位手术时间136分钟,中位淋巴结数13枚(5个N2站和1个N1站),中位出血量50 cc,术中输血4例(0.005%)。
  • 中转116例(9%),其中因出血中转24例(2%);中位住院3天,主要并发症8%。
  • 30天和90天手术死亡率分别为0.2%和0.5%;随访完整率99%,中位随访30个月(范围1-154个月)。
  • 5年分期特异性生存:IA期83%(672例)、IB期77%(281例)、IIA期68%(118例)、IIB期70%(99例)、IIIA期62%(143例,其中122例N2占73%)、IIIB期31%(8例,均无N3)。
  • 转移性NSCLC累积发生率15%(128例,95%CI 13%-18%),同侧术侧胸腔局部复发累积发生率仅3%(26例,95%CI 2%-5%)。

临床怎么用

  • 可作为机器人肺叶切除治疗NSCLC围手术期安全性与长期肿瘤学结局的参考,尤其关注病理N2患者的5年生存数据。

局限性

  • 为多中心回顾性研究,作者指出仍需进一步随访和研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Our objective is to report the world's largest series with the longest follow-up of robotic lobectomy for non-small cell lung cancer (NSCLC). METHODS: This was a multi-institutional retrospective review of a consecutive series of patients from 4 institutions' prospective robotic databases. RESULTS: There were 1339 patients (men 55%, median age 68 years). The median operative time was 136 minutes, median number of lymph nodes was 13 (5 N2 stations and 1 N1), median blood loss was 50 cc, and 4 (0.005%) patients received intraoperative transfusions. Conversions occurred in 116 patients (9%) and for bleeding in 24 (2%). Median length of stay was 3 days. Major morbidity occurred in 8%. The 30-day and 90-day operative mortality was 0.2% and 0.5%, respectively. Follow-up was complete in 99% of patients with a median follow-up of 30 months (range 1-154 months). The 5-year stage-specific survival was: 83% for the 672 patients with stage IA NSCLC, 77% for the 281 patients with stage IB, 68% for the 118 patients with stage IIA, 70% for 99 patients with IIB, 62% for 143 patients with stage IIIA (122 had N2 disease, 73%), and 31% for 8 patients with stage IIIB (none had N3 disease). The cumulative incidence of metastatic NSCLC was 15% (128 patients, 95% confidence interval, 13%-18%). The cumulative incidence of local recurrence in the ipsilateral operated chest was 3% only (26 patients, 95% confidence interval, 2%-5%). CONCLUSIONS: The oncologic results of robotic lobectomy for NSCLC are promising, especially for patients with pathologic N2 disease. However, further follow-up and studies are needed.

来源:J Thorac Cardiovasc Surg,查看原文。版权归原作者所有。

引用

  1. Cerfolio RJ, Ghanim AF, Dylewski M, et al. The long-term survival of robotic lobectomy for non-small cell lung cancer: A multi-institutional study. J Thorac Cardiovasc Surg. 2017. PMID: 29031947. doi:10.1016/j.jtcvs.2017.09.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。